Trials / Completed
CompletedNCT02762994
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
International Multi-center Comparative Randomized Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous treatment including UV-therapy and biologic drugs was registered, will receive 40, 80 or 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10. Efficacy and safety parameters will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCD-085 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2016-05-05
- Last updated
- 2021-03-23
- Results posted
- 2021-03-23
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT02762994. Inclusion in this directory is not an endorsement.